论文信息 - Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL) - 字舞流文

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A. Berrebi | U. Jaeger | H. Döhner | M. Hallek | P. Zinzani | S. Stilgenbauer | C. Wendtner | M. Kneba | P. Staib | B. Cazin | M. Hensel | M. Trněný | M. Mendila | G. Hess | J. Seymour | M. Ritgen | R. Busch | J. Catalano | A. Fink | K. Fischer | J. Mayer | G. Fingerle-Rowson | B. Eichhorst | G. Hopfinger | M. Bergmann | A. Westermann | S. Boettcher | F. C. Cappio | U. V. Gruenhagen